EGFR as a potent CAR T target in triple negative breast cancer brain metastases.

depatuxizumab (ABT-806) - AbbVie

EGFR806-specific CAR T-cell therapy - Cellevolve Bio, Seattle Children’s Therapeutics

http://www.ncbi.nlm.nih.gov/pubmed/36318382

Nov 2, 2022